Abivax (NASDAQ:ABVX) Sets New 1-Year High – Here’s Why

Abivax SA Sponsored ADR (NASDAQ:ABVX) reached a new 52-week high on Tuesday . The stock traded as high as $139.62 and last traded at $138.72, with a volume of 4152856 shares trading hands. The stock had previously closed at $114.94.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ABVX. Truist Financial set a $140.00 price objective on Abivax in a report on Monday, November 24th. Barclays assumed coverage on Abivax in a research report on Monday, October 13th. They set an “overweight” rating and a $142.00 target price for the company. Guggenheim restated a “buy” rating and issued a $175.00 price objective on shares of Abivax in a research note on Thursday. BTIG Research upped their price objective on shares of Abivax from $112.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, October 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Abivax currently has an average rating of “Moderate Buy” and an average price target of $128.73.

Abivax Stock Performance

The firm has a market cap of $10.81 billion, a price-to-earnings ratio of -80.18 and a beta of 0.49. The firm’s 50 day moving average price is $109.59 and its 200-day moving average price is $73.24. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings results on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The business had revenue of ($4.92) million for the quarter. On average, analysts anticipate that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current year.

Hedge Funds Weigh In On Abivax

Several large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its position in shares of Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after acquiring an additional 1,990 shares during the period. Affinity Asset Advisors LLC bought a new position in Abivax in the first quarter worth $1,250,000. Cubist Systematic Strategies LLC boosted its stake in Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after buying an additional 2,595 shares in the last quarter. Nantahala Capital Management LLC raised its stake in shares of Abivax by 3.3% in the 1st quarter. Nantahala Capital Management LLC now owns 1,482,994 shares of the company’s stock valued at $9,269,000 after buying an additional 46,947 shares in the last quarter. Finally, Paloma Partners Management Co bought a new position in shares of Abivax during the 1st quarter worth about $240,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.